SCHEMBL119204

SCHEMBL119204

O=C(O)c1cn2c(Cl)cccc2n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 3/20 0.51
PTGS2 P35354 3/20 0.51
KDM4E B2RXH2 2/20 0.44
ALOX15 P16050 1/20 0.44
TSHR P16473 1/20 0.44
ACMSD Q8TDX5 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
GAA P10253 1/20 0.43
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
PDE10A Q9Y233 1/20 0.38
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
MAPT P10636 1/20 0.36
CHEK1 O14757 1/20 0.36
LTK P29376 1/20 0.36
GRK5 P34947 1/20 0.36
CSNK1A1 P48729 1/20 0.36
LIMK1 P53667 1/20 0.36
TYRO3 Q06418 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3035988 0.83 PTGS1 (0.51) PTGS1PTGS2KDM4EALOX15TSHR
SCHEMBL9753622 0.81 PTGS1 (0.53) PTGS1PTGS2KDM4EALOX15TSHR
SCHEMBL4225338 0.80 CDK2 (0.48) KDM4ETDP1GAANPC1RAB9A
SCHEMBL3306389 0.79 PTGS1 (0.51) PTGS1PTGS2KDM4EALOX15TSHR
SCHEMBL119926 0.79 GAA (0.66) PTGS1PTGS2KDM4EALOX15TSHR
SCHEMBL8610107 0.79 PTGS1 (0.47) PTGS1PTGS2KDM4EALOX15TSHR
SCHEMBL3497394 0.79 PPP1CA (0.48) PTGS1PTGS2GABRA2GABRB2
SCHEMBL118187 0.77 GAA (0.75) KDM4EGAANPC1RAB9ACYP1A2
SCHEMBL8606782 0.77 PTGS1 (0.49) PTGS1PTGS2KDM4EALOX15TSHR
SCHEMBL3716081 0.77 PTGS1 (0.49) PTGS1PTGS2KDM4EALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120101093-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS HIGH POINT PHARMACEUTICALS, LLC (US) 2012-04-26 US disclosed
EP-2424866-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS -SECRETASE INHIBITORS High Point Pharmaceuticals, LLC (US) 2012-03-07 EP disclosed
WO-2010126745-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS β-SECRETASE INHIBITORS HIGH POINT PHARMACEUTICALS, LLC (US) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101093-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS BACE1, BACE2, APP PTGS1 1301/4885PTGS2 2014/4885KDM4E 2967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.